منابع مشابه
383-389 Book Reviews Fall 06
iterary studies have long been in the habit of investigating the category of the literary from various critical perspectives. Indeed, we have come to expect that a book on literature will contain a critical reflection on the limits of literature, knowing that a simple celebration of literature will obscure more than it will reveal. Such self-criticism is much harder to find in theater studies, ...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
The recent approvals of Betaseron, Avonex, and Copaxone have improved treatment options for multiple sclerosis (MS), but these therapeutics delay the progression of disease in only ~30% of the patient population. There remains an unmet need for MS therapeutics, and several new drugs enter clinical testing each year in an attempt to meet this need (37,38). This review summarizes the development ...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
This symposium was organized by P. Illes (Univ. Leipzig, Germany), A. Reichenbach (Paul-Flechsig Institute for Brain Research, Leipzig, Germany) and H. Zimmermann (Univ. Frankfurt/Main, Germany). More than 150 experts on purinergic transmission met at a historical building of the University of Leipzig in the center of the town. The symposium consisted of 32 twenty-minute-long lectures by invite...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
The 21st annual meeting of the Canadian College of Neuropsychopharmacology (CCNP) was marked by participation of an unprecedented number of registrants > 200, comprising psychiatrists, pharmacologists, and neuroscientists from Canada and the U.S.A. The presentations consisted of four plenary lectures, three award lectures, eight symposia, and 97 posters. The major themes in the meeting included...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
M. Csejtei et al. (Gedeon Richter Ltd., Budapest, Hungary) reported pharmacological studies with RGH-2716 (8-{4,4-bis(4-fluorophenyl)butyl}-3-1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro{4,5}decan-2-one), known also as TDN-345. This drug was reported to protect ischemic brain tissue from energy loss in mice at doses ranging from 3 to 30 mg/kg i.p. At 0.1 to 10 μM it blocked veratridine-i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Architectural Histories
سال: 2018
ISSN: 2050-5833
DOI: 10.5334/ah.359